奥拉单抗在软组织肉瘤中的现状与未来展望
本文综述奥拉单抗(抗PDGFRα单抗)联合多柔比星在蒽环类未治晚期软组织肉瘤中的研究现状。随机II期数据显示总生存改善但无进展生存与缓解率不成比例,机制尚不明确,需进一步转化研究及III期试验结果验证。
要点
- 奥拉单抗联合多柔比星在II期显示总生存改善,但与PFS和缓解率不成比例
- PDGFRα抑制的药效学标志与临床获益不相关,提示存在其他机制
- 抗肿瘤免疫应答和肿瘤基质改变是待验证的潜在机制
核心结论
- 奥拉单抗联合多柔比星在蒽环类未治晚期软组织肉瘤中显示总生存改善,但机制尚不明确,需进一步研究验证。
研究设计与样本
- 本文为综述,基于近期随机II期试验数据及临床前研究,讨论奥拉单抗在软组织肉瘤中的现状与未来方向。
主要发现
- 随机II期试验显示奥拉单抗联合多柔比星在蒽环类未治晚期软组织肉瘤中总生存改善前所未有。
- 总生存改善与无进展生存和缓解率不成比例。
- 临床前数据显示奥拉单抗特异性抑制PDGFRα介导的致癌信号并产生抗肿瘤效应。
- PDGFRα抑制的药效学标志与临床获益缺乏相关性,提示存在下游PDGFRα分子通路之外的机制。
- 提出的机制包括抗肿瘤免疫应答和肿瘤基质改变,但需进一步评估。
临床怎么用
- 目前奥拉单抗联合多柔比星的临床获益与机制不一致,临床应用需等待III期试验结果进一步明确。
局限性
- 奥拉单抗的确切作用机制尚未明确。
- PDGFRα抑制的药效学标志与临床获益缺乏相关性。
- 含奥拉单抗联合方案中细胞毒药物的药物特异性贡献尚未表征。
- 抗肿瘤免疫应答和肿瘤基质改变等机制需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), to doxorubicin confers an unprecedented improvement in overall survival to patients with anthracycline-naïve advanced soft tissue sarcoma. However, this result was disproportionate with progression-free survival and response rate, and consequently there are unanswered questions regarding the precise mechanism of action of olaratumab. While preclinical data show that olaratumab specifically inhibits PDGFRα-mediated oncogenic signalling with attendant anti-tumour effects, a lack of correlation between pharmacodynamics markers of PDGFRα inhibition and clinical benefit from olaratumab suggest other mechanisms beyond modulation of downstream PDGFRα molecular pathways. Proposed mechanisms of olaratumab activity include engagement of anti-tumour immune responses and alterations of the tumour stroma, but these require further evaluation. Meanwhile, the drug-specific contribution of cytotoxic agents to olaratumab-containing combinations has yet to be characterised. Ongoing and future preclinical and translational studies, coupled with the anticipated results of a phase III trial that has completed enrolment, should provide greater insight into the efficacy and mode of action of olaratumab in soft tissue sarcomas.
引用
- Antoniou G, Lee ATJ, Huang PH, et al. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018. PMID: 29413687. doi:10.1016/j.ejca.2017.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。